Clinical trial design in the neurocritical care unit

C. E. Hall; M. Mirski; Y. Y. Palesch; M. N. Diringer; A. I. Qureshi; C. S. Robertson; R. Geocadin; C. A.C. Wijman; P. D. Le Roux; Jose I. Suarez

doi:10.1007/s12028-011-9608-6

Clinical trial design in the neurocritical care unit

C. E. Hall, M. Mirski, Y. Y. Palesch, M. N. Diringer, A. I. Qureshi, C. S. Robertson, R. Geocadin, C. A.C. Wijman, P. D. Le Roux, Jose I. Suarez

Neurology

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

Clinical trials provide a robust mechanism to advance science and change clinical practice across the widest possible spectrum. Fundamental in the Neurocritical Care Society's mission is to promote Quality Patient Care by identifying and implementing best medical practices for acute neurological disorders that are consistent with the current scientific knowledge. The next logical step will be to foster rapid growth of our scientific body of evidence, to establish and disseminate these best practices. In this manuscript, five invited experts were impaneled to address questions, identified by the conference organizing committee as fundamental issues for the design of clinical trials in the neurological intensive care unit setting.

Original language	English (US)
Pages (from-to)	6-19
Number of pages	14
Journal	Neurocritical Care
Volume	16
Issue number	1
DOIs	https://doi.org/10.1007/s12028-011-9608-6
State	Published - Feb 2012

Bibliographical note

Funding Information:
Given that, large phase III clinical trials may provide the necessary tipping point required to change clinical practice, but the question that follows is, how best are major clinical trials supported, by industry or federal agencies? Large resource intensive phase III clinical trials may require complex funding strategies. The ISAT trial [36] for instance received support from multiple sponsor sources including grants from: (1) The medical research council, UK; (2) Programme Hospitalier de Recherche Clinique 1998 of the French ministry of health (AOM 98150); (3) Assistance Publique, Hopitaux de Paris (AP-HP); (4) The Canadian institutes of health research; and (5) The Stroke Association of the UK. Additionally, investigators had industry consulting and advisory agreements as well as stock interest with Microtherapeutics Inc. and Micrus Inc., which are manufacturers of microcatheters and detachable platinum coils.

Funding Information:
P01 Research Program Project Grant

Keywords

Funding
Industry
NIH
Neurocritical care
Surrogate markers

Access

10.1007/s12028-011-9608-6

OpenUrl availability

Full text

Cite this

@article{092fd4ed51974d9cb471ae53a7c5e6ee,

title = "Clinical trial design in the neurocritical care unit",

abstract = "Clinical trials provide a robust mechanism to advance science and change clinical practice across the widest possible spectrum. Fundamental in the Neurocritical Care Society's mission is to promote Quality Patient Care by identifying and implementing best medical practices for acute neurological disorders that are consistent with the current scientific knowledge. The next logical step will be to foster rapid growth of our scientific body of evidence, to establish and disseminate these best practices. In this manuscript, five invited experts were impaneled to address questions, identified by the conference organizing committee as fundamental issues for the design of clinical trials in the neurological intensive care unit setting.",

keywords = "Funding, Industry, NIH, Neurocritical care, Surrogate markers",

author = "Hall, {C. E.} and M. Mirski and Palesch, {Y. Y.} and Diringer, {M. N.} and Qureshi, {A. I.} and Robertson, {C. S.} and R. Geocadin and Wijman, {C. A.C.} and {Le Roux}, {P. D.} and Suarez, {Jose I.}",

note = "Funding Information: Given that, large phase III clinical trials may provide the necessary tipping point required to change clinical practice, but the question that follows is, how best are major clinical trials supported, by industry or federal agencies? Large resource intensive phase III clinical trials may require complex funding strategies. The ISAT trial [36] for instance received support from multiple sponsor sources including grants from: (1) The medical research council, UK; (2) Programme Hospitalier de Recherche Clinique 1998 of the French ministry of health (AOM 98150); (3) Assistance Publique, Hopitaux de Paris (AP-HP); (4) The Canadian institutes of health research; and (5) The Stroke Association of the UK. Additionally, investigators had industry consulting and advisory agreements as well as stock interest with Microtherapeutics Inc. and Micrus Inc., which are manufacturers of microcatheters and detachable platinum coils. Funding Information: P01 Research Program Project Grant",

year = "2012",

month = feb,

doi = "10.1007/s12028-011-9608-6",

language = "English (US)",

volume = "16",

pages = "6--19",

journal = "Neurocritical Care",

issn = "1541-6933",

publisher = "Humana Press",

number = "1",

}

TY - JOUR

T1 - Clinical trial design in the neurocritical care unit

AU - Hall, C. E.

AU - Mirski, M.

AU - Palesch, Y. Y.

AU - Diringer, M. N.

AU - Qureshi, A. I.

AU - Robertson, C. S.

AU - Geocadin, R.

AU - Wijman, C. A.C.

AU - Le Roux, P. D.

AU - Suarez, Jose I.

N1 - Funding Information: Given that, large phase III clinical trials may provide the necessary tipping point required to change clinical practice, but the question that follows is, how best are major clinical trials supported, by industry or federal agencies? Large resource intensive phase III clinical trials may require complex funding strategies. The ISAT trial [36] for instance received support from multiple sponsor sources including grants from: (1) The medical research council, UK; (2) Programme Hospitalier de Recherche Clinique 1998 of the French ministry of health (AOM 98150); (3) Assistance Publique, Hopitaux de Paris (AP-HP); (4) The Canadian institutes of health research; and (5) The Stroke Association of the UK. Additionally, investigators had industry consulting and advisory agreements as well as stock interest with Microtherapeutics Inc. and Micrus Inc., which are manufacturers of microcatheters and detachable platinum coils. Funding Information: P01 Research Program Project Grant

PY - 2012/2

Y1 - 2012/2

N2 - Clinical trials provide a robust mechanism to advance science and change clinical practice across the widest possible spectrum. Fundamental in the Neurocritical Care Society's mission is to promote Quality Patient Care by identifying and implementing best medical practices for acute neurological disorders that are consistent with the current scientific knowledge. The next logical step will be to foster rapid growth of our scientific body of evidence, to establish and disseminate these best practices. In this manuscript, five invited experts were impaneled to address questions, identified by the conference organizing committee as fundamental issues for the design of clinical trials in the neurological intensive care unit setting.

AB - Clinical trials provide a robust mechanism to advance science and change clinical practice across the widest possible spectrum. Fundamental in the Neurocritical Care Society's mission is to promote Quality Patient Care by identifying and implementing best medical practices for acute neurological disorders that are consistent with the current scientific knowledge. The next logical step will be to foster rapid growth of our scientific body of evidence, to establish and disseminate these best practices. In this manuscript, five invited experts were impaneled to address questions, identified by the conference organizing committee as fundamental issues for the design of clinical trials in the neurological intensive care unit setting.

KW - Funding

KW - Industry

KW - NIH

KW - Neurocritical care

KW - Surrogate markers

UR - http://www.scopus.com/inward/record.url?scp=84861094797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861094797&partnerID=8YFLogxK

U2 - 10.1007/s12028-011-9608-6

DO - 10.1007/s12028-011-9608-6

M3 - Review article

C2 - 21792753

AN - SCOPUS:84861094797

SN - 1541-6933

VL - 16

SP - 6

EP - 19

JO - Neurocritical Care

JF - Neurocritical Care

IS - 1

ER -

Clinical trial design in the neurocritical care unit

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this